New combo aims to keep leukemia from coming back after transplant
NCT ID NCT07199855
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 35 times
Summary
This phase 2 trial tests whether giving two drugs—blinatumomab and venetoclax—after a stem cell transplant can prevent relapse in adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study enrolls 24 people aged 14 to 65. The main goal is to see how many stay cancer-free for two years after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab and venetoclax
What this could lead to
If successful, this combination could help prevent leukemia from returning after a stem cell transplant, improving long-term survival for high-risk patients.
What could go wrong
This is a small, early-phase study with only 24 participants, so results may not apply to everyone. The drugs can cause serious side effects like infections or nerve problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.